CCR2 and non-small cell lung carcinoma: Furthermore, BMS-813160, a CCR2/CCR5 dual antagonist, has been studied in combination treatments in non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), and pancreatic ductal adenocarcinoma (NCT04123379, NCT03496662).